GlassScriptPhysician profile
Ian Blake Holbrook
NPI 1427468909
$1,589.82
in general payments reported to CMS, 2019-2025
29 companies · $299 in 2025
The $299 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $264 · 2020: $179 · 2022: $78.74 · 2023: $463 · 2024: $306 · 2025: $299.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,068.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,068.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $191.92 | 2019-2025 | |
| Channel Medsystems, INC. | $121.13 | 2023-2025 | |
| Gynesonics, INC. | $121.01 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
| Hologic Sales and Service, LLC | $110.71 | 2019-2025 | Myosure Tissue Removal Device, Novasure, Coolseal Generator |
| Exeltis, USA INC. | $96.33 | 2022-2024 | Slynd |
| Sumitomo Pharma America, INC. | $96.32 | 2023-2025 | Myfembree |
| Sage Therapeutics, LLC | $85.98 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $83.87 | 2019-2024 | Veozah, Myrbetriq |
| Abbvie INC. | $70.57 | 2019-2020 | |
| Pfizer INC. | $64.51 | 2019-2023 | |
| Baxter Healthcare | $62.56 | 2024-2025 | Tisseel |
| Shield Therapeutics INC | $60.83 | 2023-2024 | Accrufer |
| Daiichi Sankyo INC. | $57.90 | 2023-2025 | Injectafer |
| Amag Pharmaceuticals, INC. | $55.81 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $35.79 | 2023-2025 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $34.18 | 2019-2023 | Paragard T 380a |
| Lupin INC. | $28.64 | 2019 | |
| Meditrina | $28.28 | 2023-2025 | |
| Therapeuticsmd, INC. | $22.67 | 2019-2020 | |
| Innovation Technologies INC | $20.36 | 2024 | Irrisept |
| Medtronic, INC. | $19.11 | 2025 | Interstim |
| Ethicon US, LLC | $18.79 | 2019 | |
| Myovant Sciences INC. | $18.53 | 2022 | |
| Duchesnay USA Incorporated | $16.61 | 2019 | |
| Agile Therapeutics, INC. | $16.49 | 2022 | |
| Organon LLC | $15.15 | 2023 | Nexplanon |
| Millicent US INC | $13.66 | 2025 | Intrarosa |
| Allergan, INC. | $11.09 | 2020 | |
| Merck Sharp & Dohme LLC | $11.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ian Holbrook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.